指南与共识细菌感染、耐药与抗菌药物医院感染防控

ESCMID 免疫功能受损宿主感染研究组(ESGICH)关于靶向和生物制剂治疗安全性的共识文件:感染病学视角(细胞内信号通路:酪氨酸激酶和 mTOR 抑制剂)

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors).
指南 / 共识 · Clin Microbiol Infect · 2018-02-16

该共识由 ESCMID 免疫功能受损宿主感染研究组制定,基于计算机 Medline 检索,从感染病学视角综述靶向细胞内信号通路药物(酪氨酸激酶和 mTOR 抑制剂)的感染风险并给出预防建议。部分药物增加感染风险,需针对性预防。

要点

  • 达沙替尼与巨细胞病毒和乙型肝炎病毒再激活相关。
  • idelalisib 可能易感机会性感染,推荐抗肺孢子菌预防和巨细胞病毒预防策略。
  • Janus 激酶抑制剂显著增加感染发生率,需筛查慢性乙型肝炎和潜伏结核。

核心结论

  • 鉴于部分综述药物与感染风险增加相关,需采取特异性预防措施。

研究设计与样本

  • 制定机构为欧洲临床微生物学和感染病学会(ESCMID)免疫功能受损宿主感染研究组,方法为基于计算机的 Medline 检索,检索词为各药物或治疗家族的 MeSH 主题词。

主要发现

  • BCR-ABL 酪氨酸激酶抑制剂轻度增加总体感染风险,达沙替尼与巨细胞病毒和乙型肝炎病毒再激活相关。
  • BRAF/MEK 激酶抑制剂未显著影响感染易感性。
  • Bruton 酪氨酸激酶抑制剂(依鲁替尼)在 B 细胞恶性肿瘤患者中的感染效应难以与既往免疫抑制区分,但偶有肺孢子菌肺炎(PCP)、侵袭性真菌感染和进行性多灶性白质脑病病例报告。
  • venetoclax(抗凋亡蛋白 Bcl-2 抑制剂)未观察到感染率增加。
  • Janus 激酶抑制剂治疗显著增加感染发生率;mTOR 抑制剂治疗的癌症患者总体感染发生率增加,尤其是具有额外危险因素(既往治疗或伤口愈合延迟)者。

关键数值与推荐

  • idelalisib 可能易感机会性感染,推荐抗肺孢子菌预防和巨细胞病毒预防策略。
  • Janus 激酶抑制剂治疗前必须筛查慢性乙型肝炎病毒和潜伏结核感染,对于有额外危险因素的患者应考虑抗肺孢子菌预防。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The present review is part of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biologic therapies. AIMS: To review, from an infectious diseases perspective, the safety profile of therapies targeting different intracellular signaling pathways and to suggest preventive recommendations. SOURCES: Computer-based Medline searches with MeSH terms pertaining to each agent or therapeutic family. CONTENT: Although BCR-ABL tyrosine kinase inhibitors modestly increase the overall risk of infection, dasatinib has been associated with cytomegalovirus and hepatitis B virus reactivation. BRAF/MEK kinase inhibitors do not significantly affect infection susceptibility. The effect of Bruton tyrosine kinase inhibitors (ibrutinib) among patients with B-cell malignancies is difficult to distinguish from that of previous immunosuppression. However, cases of Pneumocystis jirovecii pneumonia (PCP), invasive fungal infection and progressive multifocal leukoencephalopathy have been occasionally reported. Because phosphatidylinositol-3-kinase inhibitors (idelalisib) may predispose to opportunistic infections, anti-Pneumocystis prophylaxis and prevention strategies for cytomegalovirus are recommended. No increased rates of infection have been observed with venetoclax (antiapoptotic protein Bcl-2 inhibitor). Therapy with Janus kinase inhibitors markedly increases the incidence of infection. Pretreatment screening for chronic hepatitis B virus and latent tuberculosis infection must be performed, and anti-Pneumocystis prophylaxis should be considered for patients with additional risk factors. Cancer patients receiving mTOR inhibitors face an increased incidence of overall infection, especially those with additional risk factors (prior therapies or delayed wound healing). IMPLICATIONS: Specific preventive approaches are warranted in view of the increased risk of infection associated with some of the reviewed agents.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Reinwald M, Silva JT, Mueller NJ, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors). Clin Microbiol Infect. 2018. PMID: 29454849. doi:10.1016/j.cmi.2018.02.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。